ES2149471T3 - Compuesto con glicolato de almidon sodico como material soporte y productos a base de dicho compuesto. - Google Patents

Compuesto con glicolato de almidon sodico como material soporte y productos a base de dicho compuesto.

Info

Publication number
ES2149471T3
ES2149471T3 ES96913671T ES96913671T ES2149471T3 ES 2149471 T3 ES2149471 T3 ES 2149471T3 ES 96913671 T ES96913671 T ES 96913671T ES 96913671 T ES96913671 T ES 96913671T ES 2149471 T3 ES2149471 T3 ES 2149471T3
Authority
ES
Spain
Prior art keywords
sodium starch
starch glycolate
active substances
support material
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96913671T
Other languages
English (en)
Inventor
Fabio Carli
Jatin J Eon Labs Manufact Shah
Edward C Eon Labs Manuf Shinal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adare Pharmaceuticals SRL
Original Assignee
Eurand International SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand International SpA filed Critical Eurand International SpA
Application granted granted Critical
Publication of ES2149471T3 publication Critical patent/ES2149471T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Abstract

SE PREPARAN COMPOSICIONES ACTIVADAS MECANICAMENTE QUE INCLUYEN SUSTANCIAS FARMACEUTICAMENTE ACTIVAS Y GLICOLATO SODICO DE ALMIDON COMO MATERIAL DE SOPORTE MEDIANTE LA CO ON DE ELEVADA ENERGIA DE LAS SUSTANCIAS FARMACEUTICAMENTE ACTIVAS Y EL GLICOLATO SODICO DE ALMIDON PARA OBTENER LAS COMPOSICIONES ACTIVADAS MECANICAMENTE QUE POSEEN VELOCIDADES AUMENTADAS DE DISOLUCION, CINETICAS MEJORADAS DE SOLUBILIZACION, BIODISPONIBILIDAD MEJORADA, Y NIVELES PICO MEJORADOS DE FARMACO EN PLASMA DE LAS SUSTANCIAS FARMACEUTICAMENTE ACTIVAS CUANDO SE COMPARAN CON LAS SUSTANCIAS ACTIVAS PER SE O CON FORMULACIONES CONOCIDAS DE LAS MISMAS.
ES96913671T 1995-04-20 1996-04-17 Compuesto con glicolato de almidon sodico como material soporte y productos a base de dicho compuesto. Expired - Lifetime ES2149471T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42543495A 1995-04-20 1995-04-20

Publications (1)

Publication Number Publication Date
ES2149471T3 true ES2149471T3 (es) 2000-11-01

Family

ID=23686568

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96913671T Expired - Lifetime ES2149471T3 (es) 1995-04-20 1996-04-17 Compuesto con glicolato de almidon sodico como material soporte y productos a base de dicho compuesto.

Country Status (11)

Country Link
EP (1) EP0822808B1 (es)
JP (1) JPH11503749A (es)
AT (1) ATE194909T1 (es)
AU (1) AU5658496A (es)
CA (1) CA2218486A1 (es)
DE (1) DE69609501T2 (es)
DK (1) DK0822808T3 (es)
ES (1) ES2149471T3 (es)
GR (1) GR3034617T3 (es)
PT (1) PT822808E (es)
WO (1) WO1996032931A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1295289B1 (it) * 1997-10-07 1999-05-04 Telos S R L Co-macinati per uso cosmetico e dermatologico
EP1409140B1 (en) * 2001-06-29 2005-08-10 Eurand Pharmaceuticals Ltd. Drug activation process with a vibrational mill
US7951399B2 (en) 2001-06-29 2011-05-31 Eurand Pharmaceuticals Ltd. Process for activation of drugs in a vibrational mill
TW200523253A (en) 2003-07-22 2005-07-16 Arena Pharm Inc Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
WO2010062323A2 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
ITMI20120092A1 (it) 2012-01-26 2013-07-27 Micro Macinazione S A Compositi di inclusione farmaco-carrier preparati con processo di attivazione meccano-chimica mediante mulini a getto di fluido ad alta energia
MX2017016413A (es) 2015-06-12 2018-08-01 Axovant Sciences Gmbh Derivados de diaril y arilheteroaril urea como moduladores del receptor 5ht2a de serotonina útiles para la profilaxis y el tratamineto de un trastorno conductual del sueño rem.
CA2992518A1 (en) 2015-07-15 2017-01-19 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5132719A (en) * 1974-09-13 1976-03-19 Yoshinobu Nakai Iyakuhinnoshorihoho
GB8403359D0 (en) * 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
US5130140A (en) * 1989-09-14 1992-07-14 Hoeschst-Roussel Pharmaceuticals Inc. Method of making direct dry compressible acetaminophen composition

Also Published As

Publication number Publication date
PT822808E (pt) 2000-12-29
WO1996032931A3 (en) 1996-11-28
JPH11503749A (ja) 1999-03-30
ATE194909T1 (de) 2000-08-15
WO1996032931A2 (en) 1996-10-24
GR3034617T3 (en) 2001-01-31
EP0822808B1 (en) 2000-07-26
AU5658496A (en) 1996-11-07
DK0822808T3 (da) 2000-10-09
DE69609501D1 (de) 2000-08-31
DE69609501T2 (de) 2001-03-29
EP0822808A2 (en) 1998-02-11
CA2218486A1 (en) 1996-10-24

Similar Documents

Publication Publication Date Title
ES2149471T3 (es) Compuesto con glicolato de almidon sodico como material soporte y productos a base de dicho compuesto.
AU6329600A (en) Foot prosthesis
UY24875A1 (es) Composiciones farmacéuticas conteniendo tetrahidrolipstatina
DE69623634D1 (de) Pharmazeutische zusammensetzung von l-dopa ethyl ester
YU10699A (sh) Upotreba glp-1, glp-1 analoga i glp-1 derivata za proizvodnju leka
AU8183198A (en) Nanocrystalline formulations of human immunodeficiency virus (hiv) protease inhibitors using cellulosic surface stabilizers and methods of making such formulations
NO20002786D0 (no) Adamantanderivater
CO4940403A1 (es) Formulaciones de liberacion prolongada de derivados de eri- tromicina
AU7915898A (en) Pharmaceutical composition in form of solid lipidic microparticles suitable to parenteral administration
MY108864A (en) Peptide-carbohydrate conjugates generating t-cell immunity
AU7001001A (en) Modified forms of pharmacologically active agents and uses therefor
BG103714A (en) Pararacetamol-containing tablet
DE69433355D1 (de) Taxane ohne die c-9 oxo gruppe und diese enthaltende pharmazeutische präparate
EP1219596A4 (en) Salicylamide DERIVATIVES
BG105570A (en) Pharmaceutical compositions for modified release insulin sensitiser
AU8025998A (en) Biologically active materials
ATE261425T1 (de) Erythromycin-derivate mit antibiotischer wirkung
AU3445489A (en) Luminide and macroluminide class of pharmaceuticals
AU5685300A (en) Solid preparations containing paroxetine
ES2165509T3 (es) Composiciones terapeuticas efervescentes.
PL1499278T3 (pl) Farmaceutyczna postać użytkowa o natychmiastowym uwalnianiu zawierająca polimorficzny tibolon
ES2082524T3 (es) Medicamento de liberacion retardada que contiene un derivado de dihidropiridina en forma de nanosol y su preparacion.
UA66809C2 (uk) Спосіб лікування гіперглікемії похідною тіазолідиндіону
JO1766B1 (en) Effective new compounds
ECSP993215A (es) Nueva composicion y uso

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 822808

Country of ref document: ES